Adjuvant trastuzumab in HER2-positive breast cancer.
Standard
Adjuvant trastuzumab in HER2-positive breast cancer. / Slamon, Dennis; Eiermann, Wolfgang; Robert, Nicholas; Pienkowski, Tadeusz; Martin, Miguel; Press, Michael; Mackey, John; Glaspy, John; Chan, Arlene; Pawlicki, Marek; Pinter, Tamas; Valero, Vicente; Liu, Mei-Ching; Sauter, Guido; von Minckwitz, Gunter; Visco, Frances; Bee, Valerie; Buyse, Marc; Bendahmane, Belguendouz; Tabah-Fisch, Isabelle; Lindsay, Mary-Ann; Riva, Alessandro; Crown, John; Group, Breast Cancer International Research.
In: NEW ENGL J MED, Vol. 365, No. 14, 14, 2011, p. 1273-1283.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Adjuvant trastuzumab in HER2-positive breast cancer.
AU - Slamon, Dennis
AU - Eiermann, Wolfgang
AU - Robert, Nicholas
AU - Pienkowski, Tadeusz
AU - Martin, Miguel
AU - Press, Michael
AU - Mackey, John
AU - Glaspy, John
AU - Chan, Arlene
AU - Pawlicki, Marek
AU - Pinter, Tamas
AU - Valero, Vicente
AU - Liu, Mei-Ching
AU - Sauter, Guido
AU - von Minckwitz, Gunter
AU - Visco, Frances
AU - Bee, Valerie
AU - Buyse, Marc
AU - Bendahmane, Belguendouz
AU - Tabah-Fisch, Isabelle
AU - Lindsay, Mary-Ann
AU - Riva, Alessandro
AU - Crown, John
AU - Group, Breast Cancer International Research
PY - 2011
Y1 - 2011
N2 - Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.
AB - Trastuzumab improves survival in the adjuvant treatment of HER-positive breast cancer, although combined therapy with anthracycline-based regimens has been associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a new nonanthracycline regimen with trastuzumab.
KW - Humans
KW - Female
KW - Middle Aged
KW - Survival Rate
KW - Disease-Free Survival
KW - Chemotherapy, Adjuvant
KW - Intention to Treat Analysis
KW - Antibodies, Monoclonal, Humanized
KW - Anthracyclines/adverse effects/therapeutic use
KW - Antibodies, Monoclonal/adverse effects/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Breast Neoplasms/drug therapy/mortality
KW - Heart Failure/chemically induced
KW - Leukemia/chemically induced
KW - Receptor, erbB-2
KW - Stroke Volume/drug effects
KW - Humans
KW - Female
KW - Middle Aged
KW - Survival Rate
KW - Disease-Free Survival
KW - Chemotherapy, Adjuvant
KW - Intention to Treat Analysis
KW - Antibodies, Monoclonal, Humanized
KW - Anthracyclines/adverse effects/therapeutic use
KW - Antibodies, Monoclonal/adverse effects/therapeutic use
KW - Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
KW - Breast Neoplasms/drug therapy/mortality
KW - Heart Failure/chemically induced
KW - Leukemia/chemically induced
KW - Receptor, erbB-2
KW - Stroke Volume/drug effects
M3 - SCORING: Journal article
VL - 365
SP - 1273
EP - 1283
JO - NEW ENGL J MED
JF - NEW ENGL J MED
SN - 0028-4793
IS - 14
M1 - 14
ER -